Neurogene Inc reports results for the quarter ended June 30 - Earnings Summary

• Neurogene Inc NGNE.OQ reported a quarterly adjusted loss of $1.05​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.09. The mean expectation of seven analysts for the quarter was for a loss of $1.16 per share. Wall Street expected results to range from $-1.28 to $-1.04 per share.

• Reported revenue was zero​; analysts expected zero.

• Neurogene Inc's reported EPS for the quarter was a loss of $1.05​.

• Neurogene Inc shares had risen by 41.9% this quarter and lost 7.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 2.1% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Neurogene Inc is $46.00, about 53.9% above its last closing price of $21.22

This summary was machine generated from LSEG data August 11 at 08:44 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)